.jpg "Seattle Genetics (NASDAQ: SGEN)")
Oppenheimer analyst Leah R. Cann maintained a Hold rating on Seattle Genetics (NASDAQ: SGEN) today. The company’s shares opened today at $71.61.
Cann commented:
“Tisotumab vedotin is one of two mid-stage clinical assets in Seattle Genetics’ pipeline. Early data, presented this past weekend at ESMO for the potentially registrational innovaTV 204 study, are encouraging in cervical cancer. Seattle Genetics now has four late-stage development programs planned or in registration studies, which we believe really strengthens the pipeline. Based on the current stage of development of tisotumab vedotin, our outlook for the company’s revenue remains unchanged for 2018-22.”
According to TipRanks.com, Cann is a 4-star analyst with an average return of 8.5% and a 46.1% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Seattle Genetics with a $91.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $84.37 and a one-year low of $47.75. Currently, Seattle Genetics has an average volume of 767.7K.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. Last month, Vaughn Himes, the CTO of SGEN sold 5,000 shares for a total of $384,962.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seattle Genetics, Inc. engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product ADCETRIS is an antibody-drug encompassing several settings for the treatment of relapsed Hodgkin lymphoma, for relapsed systemic anaplastic large cell lymphoma, or sALCL, and for certain types of cutaneous T-cell lymphoma, or CTCL. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
